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7Drug-eluting stents vs. bare metal stents in patients with
cardiogenic shock: a comparison by propensity score analysis
Milosz Jaguszewskia,, Jelena-Rima Ghadria,, Burkhardt Seifertb,
Thierry Hiestanda, Paola Herreraa, Oliver Gaemperlia, Ulf Landmessera,
Willibald Maiera, Brahmajee K. Nallamothuc, Stephan Windeckerd,
Thomas F. Lu¨schera and Christian TemplinaBackground In patients with cardiogenic shock, data on the
comparative safety and efficacy of drug-eluting stents
(DESs) vs. bare metal stents (BMSs) are lacking. We sought
to assess the performance of DESs compared with BMSs
among patients with cardiogenic shock undergoing
percutaneous coronary intervention (PCI).
Methods Out of 236 patients with acute coronary
syndromes complicated by cardiogenic shock, 203 were
included in the final analysis. The primary endpoint included
death, and the secondary endpoint of major adverse cardiac
and cerebrovascular events (MACCEs) included the
composite of death, myocardial infarction, any repeat
revascularization and stroke. Patients were followed for a
minimum of 30 days and up to 4 years. As stent assignment
was not random, we performed a propensity score analysis
to minimize potential bias.
Results Among patients treated with DESs, there was a
lower risk of the primary and secondary endpoints
compared with BMSs at 30 days (29 vs. 56%, P<0.001; 34
vs. 58%, PU0.001, respectively) and during long-term
follow-up [hazard ratio 0.43, 95% confidence interval (CI)
0.29–0.65, P<0.001; hazard ratio 0.49, 95% CI 0.34–0.71,
P<0.001, respectively]. After propensity score adjustment,
all-cause mortality was reduced among patients treated
with DESs compared with BMSs both at 30 days [adjusted
odds ratio (OR) 0.26, 95% CI 0.11–0.62; PU0.002] and
during long-term follow-up (adjusted hazard ratio 0.40, 95% Copyright © 2015 Wolters Kluwer
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among patients treated with DESs compared with those
treated with BMSs at 30 days (adjusted OR 0.42, 95% CI
0.19–0.95; PU0.036). The difference in MACCEs between
devices approached significance during long-term follow-
up (adjusted hazard ratio 0.60, 95% CI 0.34–1.01;
PU0.052).
Conclusion DESs appear to be associated with improved
clinical outcomes, including a reduction in all-cause
mortality compared with BMSs among patients undergoing
PCI for cardiogenic shock, possibly because of a
pacification of the infarct-related artery by anti-inflammatory
drug. The results of this observational study require
confirmation in an appropriately powered randomized trial.
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Cardiogenic shock is a life-threatening complication of
acute coronary syndromes (ACSs) occurring in approxi-
mately 5–10% of patients.1,2 Indeed, cardiogenic shock is
associated with a high mortality ranging between 30 and
80%.3–5 This poor prognosis is determined in part by the
amount of myocardium at risk, the timeliness of revas-
cularization, the use of assist devices (mechanical support),
adjunctive medical therapy and the patients’ age.1,6
Recently, it has been suggested that the type of stent
used in primary percutaneous coronary interventions
(pPCIs) might impact on outcomes of patients withACS. Indeed, drug-eluting stents (DESs) reduce neoin-
timal hyperplasia when compared with bare metal stents
(BMSs); however, data on the safety and performance of
DESs in ACS are limited.7,8 The Harmonizing Outcomes
With Revascularization And Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trial suggested that pacli-
taxel-eluting stents may be used in patients with ST-
segment elevation myocardial infarction (STEMI) for
improving the outcomes.7 However, in line with previous
smaller randomized clinical trials, the mortality was
similar in both BMS and paclitaxel-eluting stent groups.7
We recently showed in the randomized Comparison of
Biolimus Eluted From an Erodible Stent Coating With
Bare Metal Stents in Acute ST-Elevation Myocar-
dial Infarction (COMFORTABLE) AMI trial that Health, Inc. All rights reserved.
DOI:10.2459/JCM.0000000000000106
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adverse cardiac and cardiovascular events (MACCEs) in
patients with ACS compared to BMS.9 A limitation of
both the HORIZONS-AMI trial and the COMFORTA-
BLE AMI trial, however, was the very small number of
patients with cardiogenic shock.7,9
Therefore, all-comers studies on patients with AMI
would be required for determining the true effects of
DES implantation compared with BMS on clinical out-
comes in high-risk patients. To address the limitations of
previously published data, we aimed to compare DES
with BMS in patients with cardiogenic shock using a
propensity score analysis to adjust for imbalances in
baseline characteristics.
Methods
Patient population
Consecutive patients referred for PCI between 1 June
2007 and 1 July 2012 to the University Heart Centre,
Department of Cardiology of the University Hospital of
Zurich, with the diagnosis of ACS, were included in the
Zurich ACS-Registry, of whom 236 were complicated by
cardiogenic shock. All patients with cardiogenic shock on
admission were considered for enrollment, if at least
one DES or BMS had been implanted. Patients were
excluded from the present study, if early surgical
revascularization or PCI without stent implantation was
performed (Fig. 1). Patients who received both DES and
BMS were also excluded from the final analysis. All
patients included in the final analysis (n¼ 203) were
linked to the long-term follow-up. Due to the retrospec-
tive nature of this study, the need for informed consent
was waived by the institutional review board (local ethics
committee, University Hospital Zurich, Switzerland).
Definitions
The diagnosis of STEMI was based on a new ST-seg-
ment elevation of at least 1 mm in two or more contiguous
leads or if a new left bundle branch block (LBBB) was
identified accompanied with elevated cardiac serum Copyright © 2015 Wolters Kluwe
Fig. 1
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Flow chart of the study enrolment. BMS, bare metal stent; CABG, coronartroponin T level above the threshold for myocardial
necrosis. Non-ST-segment elevation myocardial infarc-
tion (NSTEMI) was defined as the elevation of bio-
markers of myocardial necrosis (e.g., troponin) without
ST-segment elevation in ECG in the setting of angina.
Cardiogenic shock was defined as persistent SBP less
than 90 mmHg not responsive to fluid supplementation
or the need for vasopressor agents with evidence of
pulmonary edema and systemic signs of hypoperfusion.2
Cardiogenic shock was also considered when preserved
SBP was more than 100 mmHg achieved by means of
vasopressors or intra-aortic balloon pump (IABP) sup-
port.2 Full revascularization was defined as the complete
reperfusion of all ischemic myocardial territories. Areas of
old infarction with no viable myocardium was not reper-
fused during the acute course of ACS.
Procedures
Coronary angiography through the femoral access was
performed on an Allura 9 (Philips Healthcare, The Lei-
den, Netherlands) and an Allura XPER FD10/10 (Philips
Medical) catheterization equipment in the Andreas
Gruentzig Catheterization Laboratories of the University
Hospital of Zurich, Switzerland, following a protocol,
which consisted of a biplane angiography of the left
coronary artery with two radiation exposures in four
orientations and of the right coronary artery with two
exposures in two orientations. Additional views were
performed at the operator’s discretion, if necessary.
Two independent cardiologists evaluated coronary ste-
nosis grade, Thrombolysis in Myocardial Infarction
(TIMI) grade flow as well as the presence of thrombus.
Patients enrolled into the registry received either DES
[i.e. PROMUS (Boston Scientific, Natick, Massachusetts,
USA), Xience V (Abbott Vascular, Santa Clara, California,
USA), Cypher (Cordis Company, Bridgeton, New Jersey,
USA), Taxus (Boston Scientific), Biomatrix (Biosensors
Europe SA, Morges, Switzerland) or Orsirio (Biotronik
SE & Co. KG, Berlin, Germany) or BMS (Multilink by
Guidant Corporation, Indianapolis, Indiana, USA);
Skylor (INVATEC S.p.A, Roncadelle, Italy); Pro-Kineticr Health, Inc. All rights reserved.
diogenic shock
alysis
mplantation
n = 86
patients did not undergo revascularization
patients were referred for CABG after angiogiography
atients underwent balloon angioplasty alone
atients received both BMS and DES
y artery bypass grafting; DES, drug-eluting stent.
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Minneapolis, Minnesota, USA) based on the operator’s
discretion.
Manual thrombectomy was performed with the use of the
Export catheter (Medtronic Inc., Tolochenaz, Switzer-
land). Intravenous heparin was routinely administered
with a minimal dose of 5000 IU or a dose of 70–100 IU/kg
to maintain an activated clotting time of greater than
250 s. Dual antiplatelet therapy, including a loading dose
of 600 mg of clopidogrel or 60 mg of prasugrel (if not
previously on clopidogrel or prasugrel) and 500 mg of
acetylsalicylic acid (if not previously on regular aspirin),
was provided in all patients before or during the inter-
ventional procedure. All patients were expected to
continue clopidogrel or prasugrel therapy for at least
12 months after discharge.
The choice of the treatment strategy, including stent type,
glycoprotein IIb/IIIa antagonist or bivalirudin adminis-
tration and thrombectomy catheters’ use, was up to the
physician’s discretion. The operators based this decision
on their clinical judgment integrating the visual angiogra-
phy finding with all available clinical information.
SYNTAX score analysis
SYNTAX score assessment was performed by a cardiol-
ogist blinded to the clinical outcomes of the patients
using a scoring system for all significant lesions (50%) in
the vessels 1.5 mm or greater in diameter by applying a
dedicated SYNTAX score algorithm. SYNTAX score was
calculated using angiography just after the first dilatation
of the culprit vessel to include all significant lesions.
However, if the culprit vessel was occluded before
PCI, the lesion was scored as an acute occlusion with
the duration of less than 3 months.
Study endpoints
The primary endpoint of the present study was all-cause
mortality, and the secondary endpoint MACCE was the
composite of death, myocardial infarction (MI), any
repeat revascularization and stroke at 30 days and up
to 4 years. We also evaluated the rate of ischemia-driven
target lesion revascularization (TLR) and definite stent
thrombosis as defined by the ARC criteria. TLR was
defined as repeat intervention to treat a luminal diameter
stenosis of at least 50% in the stent or within the 5-mm
borders proximal or distal to the stent and after the event
of angina. Postdischarge observation was obtained as part
of our hospital quality assurance using a standardized
clinical questionnaire.
Statistical analysis
For statistical analysis, IBM SPSS Statistics 20 (IBM
Corp, Armonk, New York, USA) was used. Continuous
data were expressed as mean values (standard deviation)
or median with interquartile range and compared using an
independent samples t-test or the Mann–Whitney U-test. Copyright © 2015 Wolters KluwerCategorical data were reported as proportions and evalu-
ated by the Pearson’s x2 or the Fisher’s exact test, where
appropriate. Overall death and MACCEs were analyzed
using the Kaplan–Meier time-to-event curves and were
compared between DES and BMS using the log-rank test.
All tests were two-sided and a P< 0.05 was considered as
statistically significant.
As an early benefit of DES would be unlikely, we
performed a sensitivity analysis for assessing differences
between the two stent groups in all-cause mortality and
MACCE 2 days after stent placement.
Furthermore, to limit the observational character of the
study, we also performed a propensity score analysis. For
the computation of the propensity score, the following
variables were included into a nonparsimonious logistic
regression with DES as dependent variable: age, sex,
STEMI on admission, hypertension, diabetes, smoking,
hypercholesterolemia, family history, obesity, known
stroke, known MI, known coronary artery disease, heart
rate, SBP, DBP, left ventricular ejection fraction, out-of-
hospital resuscitation, type of cardiac arrest, use of vaso-
pressors, use of IABP, intubation, one-time urgent full
revascularization, Global Registry of Acute Coronary
Events (GRACE) score risk, use of glycoprotein IIb/IIIa
antagonist and use of thrombectomy; angiographic
analysis: SYNTAX score, culprit lesion and its segment,
TIMI grade flow before PCI, presence of chronic total
occlusion and stent length; laboratory values on admis-
sion: creatinine, glomerular filtration rate, myoglobin,
creatine kinase, creatine kinase-muscle brain type frac-
tion, N-terminal brain-type natriuretic peptide, lactate
dehydrogenase, aspartate aminotransferase, alanine ami-
notransferase, hemoglobin and red blood cells, white
blood cells (WBCs); drug administration before presen-
tation: aspirin, clopidogrel, prasugrel, statin, b-blocker,
angiotensin-converting enzyme inhibitors, diuretics, sar-
tans, calcium channel blockers and vitamin K antagonists.
Variables with a skewed distribution were logarithmically
transformed before analysis. Missing values were replaced
by multiple regression imputation for the respective
analysis. The model was well calibrated (the Hosmer–
Lemeshow test x2 8.3, 8 df, P¼ 0.40) and highly discri-
minating (c-value 0.91). The validity of logistic regression
was assessed using the Hosmer–Lemeshow test and pro-
portional hazard in Cox regression was estimated visually.
Finally, logistic regressions for 30-day event rates of death
and MACCE, and Cox regressions for long-term death and
MACCE, respectively, as dependent variables, and DES
and the propensity score, divided in quintiles, as indepen-
dent variables were performed.
Results
Baseline characteristics
Out of 236 patients, 203 patients with cardiogenic shock
were included into the final analysis. Of those, 157 Health, Inc. All rights reserved.
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of STEMI and 46 patients (23%) with NSTEMI. The
mean age of the total study population was 63.9 11.6
years, and 79% (n¼ 160) were men. DESs were
implanted in 58% (n¼ 117) and BMSs in 42% (n¼ 86)
of all patients. Of the patients treated with DESs, 50%
(n¼ 59) received everolimus-eluting stents, 31% (n¼ 36)
received zotarolimus-eluting stents and 19% (n¼ 22) Copyright © 2015 Wolters Kluwe
Table 1 Baseline characteristics, drug-eluting stent vs. bare metal ste
Variable DES (n¼117)
Age (years) 62.4 (11.1)
Female sex 24 (21%)
STEMI 91 (78%)
NSTEMI 26 (22%)
GRACE score
In-hospital death 266 (31.1)
In-hospital deathþMI 198 (26.8)
6-month death 400 (48.8)
6-month deathþMI 319 (36.9)
Cardiovascular risk factors
Arterial hypertension 60 (51%)
Dyslipidemia 39 (33%)
Smoking 58 (50%)
Diabetes mellitus 19 (16%)
Obesity 26 (22%)
Positive family history 34 (29%)
Cumulative cvRF 2.2 (1.4)
Cardiovascular history
CAD 20 (17%)
MI 15 (13%)
Stroke 2 (2%)
Laboratory values, maximal values
Creatinine (mmol/l) 122 (94–194)
NT-proBNP (ng/l) 3801 (1459–10746)
WBCs (g/l) 17.6 (13.5–23.0)
hsCRP (ng/l) 160 (66–254)
Myoglobin (mg/l) 2255 (918–4250)
Creatine kinase (U/l) 3244 (1348–6355)
hsTnT (mg/l) 7.3 (2.7–14.1)
LDH (U/l) 829 (546–1520)
ASPAT (U/l) 432 (188–756)
ALAT (U/l) 136 (86–248)
Hemodynamics
Heart rate (b.p.m.) 88.6 (24.8)
SBP (mmHg) 90.5 (13.3)
DBP (mmHg) 54.9 (10.1)
LVEF (%) 35.9 (9.8)
LVEDP (mmHg) 22.5 (8.1)
IABP 93 (80%)
Reanimation 81 (69%)
First out-of-hospital REA 68 (58%)
First in-hospital REA 15 (13%)
Intubation 80 (68%)
Ventricle fibrillation as first rhythm 59 (54%)
PICCO catheter 8 (7%)
Coolguard 33 (28%)
Impella/ECMO 3 (3%)
Vasopressors 73 (62%)
Medication on admission
Aspirin 39 (34%)
Clopidogrel/prasugrel 13 (11%)
ACE inhibitor or ARB 19 (17%)
b-Blocker 31 (27%)
Statin 33 (29%)
Diuretic 14 (12%)
Calcium blocker 14 (12%)
Data are presented as n (%) or mean standard deviation or median with interquartile
angiotensin-receptor blocker; ASPAT, aspartate transaminase; BMS, bare metal stent; C
CRP, C-reactive protein; cvRF, cardiovascular risk factors; DES, drug-eluting stent; ECM
Global Registry of Acute Coronary Events; hsTnT, high sensitive troponin T; IABP, intr
diastolic pressure; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
prohormone brain natriuretic peptide; REA, reanimation; STEMI, ST-segment elevatioreceived other DESs (biolimus-eluting, paclitaxel-elut-
ing, sirolimus-eluting or tacrolimus-eluting stents). The
risk profiles of the two groups of patients treated with
DES or BMS implantation were similar (Tables 1 and 2).
The mean number of risk factors was 2.2 1.4 and most
patients were classified as high risk by GRACE risk score
with a mean value for in-hospital death of 266 30.7
(range 164–338) and the composite of death and MI ofr Health, Inc. All rights reserved.
nt (nU203)
BMS (n¼86) P value
65.9 (12.1) 0.02
19 (22%) 0.86
66 (77%) 0.87
20 (23%) 0.87
266 (30.3) 0.81
201 (25.6) 0.34
388 (54.3) 0.25
315 (40.0) 0.59
48 (56%) 0.57
27 (31%) 0.88
40 (47%) 0.67
17 (20%) 0.58
20 (23%) 0.87
23 (27%) 0.75
2.2 (1.4) 0.99
12 (14%) 0.57
8 (9%) 0.51
3 (4%) 0.65
138 (109–249) 0.05
5002 (1956–13182) 0.12
19.9 (13.3–22.3) 0.80
157 (72–261) 0.77
1874 (878–4261) 0.56
1989 (1087–4377) 0.05
5.65 (2.1–11.0) 0.09
1527 (830–2487) 0.86
297 (143–700) 0.38
148 (79–275) 0.50
88.3 (25.3) 0.92
88.2 (16.3) 0.34
53.9 (12.2) 0.54
35.9 (10.4) 0.73
23.8 (7.1) 0.46
64 (74%) 0.40
54 (63%) 0.37
47 (55%) 0.67
7 (8%) 0.36
61 (71%) 0.76
34 (43%) 0.58
11 (13%) 0.22
16 (19%) 0.14
4 (5%) 0.46
59 (69%) 0.38
29 (34%) 0.98
9 (11%) 0.88
16 (19%) 0.70
20 (23%) 0.39
20 (23%) 0.55
12 (14%) 0.68
9 (11%) 0.71
range. ACE, angiotensin-converting enzyme; ALAT, alaninaminotransferase; ARB,
AD, coronary artery disease; CK-MB, creatine kinase muscle brain type-isoenzyme;
O, extracorporeal membrane oxygenation; GFR, glomerular filtration rate; GRACE,
a-aortic balloon pump; LDH, lactate dehydrogenases; LVEDP, left ventricular end-
NSTEMI, non-ST-segment elevation myocardial infarction; pro-BNP, N-terminal
n myocardial infarction; WBCs, white blood cells.
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Table 2 Angiographic and procedural profile, drug-eluting stent vs.
bare metal stent (nU203)
Variable DES (n¼117) BMS (n¼86) P value
SYNTAX score 30.4 (16.5) 31.5 (18.1) 0.69
SYNTAX score 22 41 (35%) 28 (33%) 0.71
SYNTAX score 23–32 31 (27%) 23 (27%) 0.97
SYNTAX score 33þ 45 (39%) 35 (41%) 0.75
SVD 36 (31%) 19 (22%) 0.17
2-Vessel disease 40 (34%) 28 (33%) 0.81
3-Vessel disease 41 (35%) 39 (45%) 0.14
CTO 36 (31%) 27 (31%) 0.92
Full revascularization 94 (80%) 64 (74%) 0.39
No. of lesions 2.9 (1.9) 3.5 (2.1) 0.18
No. of stents implanted 2.1 (1.3) 1.7 (0.8) 0.08
Total length implanted 44.4 (28.1) 36.9 (19.2) 0.14
Baseline TIMI flow grade 0 94 (80%) 71 (83%) 0.39
TIMI flow grade after PCI
TIMI flow grade 3 109 (93%) 75 (87%) 0.15
TIMI flow grade 1/2 6 (5%) 9 (10%) 0.15
TIMI flow grade 0 2 (2%) 2 (2%) 0.75
Thrombectomy 64 (55%) 26 (30%) 0.001
Glycoprotein IIb/IIIa 45 (39%) 22 (26%) 0.07
Culprit lesion
Left main 10 (9%) 4 (5%) 0.28
LAD 72 (62%) 33 (38%) 0.001
LCX 17 (15%) 11 (13%) 0.72
RCA 12 (10%) 37 (43%) <0.001
Bypass 6 (5%) 1 (1%) 0.13
Segment
Ostial/proximal segment 94 (80%) 60 (70%) 0.08
Medial segment 17 (15%) 17 (20%) 0.32
Distal segment 6 (5%) 9 (11%) 0.15
Data are presented as n (%) or meanSD. BMS, bare metal stent; CTO, chronic
total occlusion; DES, drug-eluting stent; LAD, left anterior descending; LCX, left
circumflex artery; MVD, multivessel disease; RCA, right coronary artery; SVD,
single-vessel disease; TIMI, thrombolysis in myocardial infarction.199 26.3 (range 111–262). The mean left ventricular
ejection fraction was 35.9 10.0% by left ventricle angio-
graphy, and the average left ventricular end-diastolic
pressure was 23.0 7.7 mmHg. The average Syntax score
was 30.8 17.2 with a maximal value of 88. No significant
differences were documented between DES and BMS
groups in average WBC level on admission (15.8 6.7 vs. Copyright © 2015 Wolters Kluwer
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A 30-day (a) and long-term mortality (b) for patients with drug-eluting stents14.9 5.2 g/l, P¼ 0.59) and maximal WBC [17.6 (13.5–
23.0) vs. 19.9 (13.3–22.3) g/l, P¼ 0.80]. In addition, mean
high-sensitivity C-reactive protein (hsCRP) on admission
was similar for both DESs and BMSs (34.8 68.0 vs.
37.7 59.5 ng/l, P¼ 0.32), as well as after maximal hsCRP
[DES vs. BMS: 160 (66–254) vs. 157 (72–261) ng/l,
P¼ 0.77]. To exclude potential differences in blood
values on admission, all laboratory profiles were enclosed
into the propensity score analysis. We did not document
any significant differences in maximal laboratory values
(Table 1). The baseline characteristics of the study
population are summarized in Table 1. The angiographic
and procedural profile is shown in Table 2.
The long-term follow-up averaged 446 589 days for the
entire study population (DES vs. BMS: 494 585 vs.
379 592 days, respectively; P¼ 0.17). The mean follow-
up of patients who survived 30 days was 790 589 days
(DES vs. BMS: 739 577 vs. 900 608 days, respect-
ively; P¼ 0.18).
Glycoprotein IIb/IIIa therapy was administered in 33% of
patients (n¼ 67), whereas thrombectomy was performed
in 44% (n¼ 90) of patients. None of the patients under-
went fibrinolysis before presentation. Full revasculari-
zation was documented in 78% (n¼ 158) of patients with
a mean stent use of 1.9 1.1 per patient (Table 2). There
were no complications related to the passage or deploy-
ment of the balloon or stent. In one patient, no reflow
phenomenon was observed after BMS implantation.
Clinical outcomes
The overall mortality rate at 30 days was 40% (n¼ 82). In
the unadjusted analysis, the primary endpoint of all-cause
mortality was significantly lower among patients treated
with DESs compared with BMSs at 30 days (29 vs. 56%,
P< 0.001) (Fig. 2a). Similar findings were obtained Health, Inc. All rights reserved.
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Table 3 Clinical outcomes, drug-eluting stent vs. bare metal stent (nU203)
Overall analysis
Before adjustment After propensity score analysis adjustment
DES (n¼117) BMS (n¼86) P Adjusted OR (95% CI) P
30-day follow-up
All-cause death 34 (29%) 48 (56%) <0.001 0.26 (0.11–0.62) 0.002
Cardiac death 33 (28%) 47 (55%) <0.001 0.27 (0.11–0.64) 0.003
MACCE 40 (34%) 50 (58%) 0.001 0.42 (0.19–0.95) 0.036
HR (95% CI) P Adjusted HR (95% CI) P
Long-term follow-up
All-cause death 0.43 (0.29–0.65) <0.001 0.40 (0.22–0.72) 0.002
Cardiac death 0.45 (0.30–0.69) <0.001 0.41 (0.23–0.76) 0.004
MACCE 0.49 (0.34–0.71) <0.001 0.60 (0.34–1.01) 0.052
Sensitivity analysis
Before adjustment After propensity score analysis adjustment
HR (95% CI) P Adjusted HR (95% CI) P
Long-term follow-up
All-cause death 0.44 (0.27–0.69) <0.001 0.34 (0.18–0.67) 0.002
Cardiac death 0.46 (0.29–0.74) 0.001 0.36 (0.18–0.71) 0.003
MACCE 0.50 (0.33–0.76) 0.001 0.58 (0.33–1.02) 0.058
BMS, bare metal stent; DES, drug-eluting stent; HR, hazard ratio; MACCE, major adverse cardiac and cerebrovascular event; OR, odds ratio.during long-term follow-up [hazard ratio 0.43, 95% confi-
dence interval (CI) 0.29–0.65, P< 0.001) (Fig. 2b).
Patients treated with DESs showed a better outcome than
those receiving BMSs for all-cause mortality, especially at
30 days after the index event. MACCE rate was also lower
in patients receiving a DES compared with those receiving
a BMS, both at 30 days (34 vs. 58%, P¼ 0.001) and during
long-term follow-up (hazard ratio 0.49, 95% CI 0.34–0.71,
P< 0.001) (Table 3, Fig. 3a and b).
The rate of 30-day definite stent thrombosis was similar
in both study populations (P¼ 0.14). Only one case of late
stent thrombosis was observed in the DES group. How-
ever, the difference in ischemia-driven TLR for DES vs.
BMS approached significance at the long-term follow-up
(0.8 vs. 6%, respectively; P¼ 0.066) in this setting.
Propensity score analysis ascertainment
After propensity score adjustment, we noticed a signifi-
cant reduction in all-cause mortality in patients receiving
DESs compared with those receiving BMSs both at 30
days [adjusted odds ratio (OR) 0.26, 95% CI 0.11–0.62;
P¼ 0.002] and during long-term follow-up [adjusted
hazard ratio (AHR) 0.40, 95% CI 0.22–0.72; P¼ 0.002]
(Fig. 4a and b). Similarly, there was a significant differ-
ence in the rates of MACCE among patients receiving
DESs as compared with BMSs in the propensity score
adjustment analysis at 30 days (adjusted OR 0.42, 95% CI
0.19–0.95; P¼ 0.036) (Fig. 5a). During long-term follow-
up, the difference between DES and BMS groups
approached significance with respect to overall MACCE
rate (AHR 0.60, 95% CI 0.34–1.01; P¼ 0.052) (Table 3,
Fig. 5b). Copyright © 2015 Wolters KluweA sensitivity analysis
The significantly lower event rate for long-term death and
MACCE among patients treated with DESs as compared
with BMSs remained unchanged after exclusion of all
events occurring within the first 2 days after admission
(hazard ratio 0.44, 95% CI 0.27–0.69, P< 0.001; hazard
ratio 0.50, 95% CI 0.33–0.76, P¼ 0.001, respectively).
Likewise, after propensity score adjustment, the long-term
rates of death and MACCE in the DES group remained
lower compared with the BMS group (AHR 0.34, 95% CI
0.18–0.67, P¼ 0.002; AHR 0.58, 95% CI 0.33–1.02,
P¼ 0.058, respectively) (Table 3).
Discussion
This study for the first time suggests that in patients
presenting with an ACS and cardiogenic shock, the
implantation of DES is associated both with a lower
mortality and a lower risk of MACCE as compared with
BMS.
In spite of all the progress made in the management of
patients with ACS in the last decades, cardiogenic shock
remains a severe complication associated with a markedly
increased mortality and MACCE rate compared with
hemodynamically stable patients.2 In the present study,
the overall 30-day mortality rate was 40%, which is
comparable with those in other shock trials.10,11 In the
Should We Emergently Revascularize Occluded Coron-
aries for Cardiogenic Shock trial and in registry data,
mortality varied from 22 up to 88% depending on the
presence or absence of clinical predictors, including
previous MI and the treatment strategies.10,11 As
expected, early revascularization improved survival rater Health, Inc. All rights reserved.
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A 30-day (a) and long-term major adverse cardiac and cerebrovascular events (MACCEs) (b) for patients with drug-eluting stents (DESs, green) and
bare metal stents (BMSs, blue), unadjusted analysis.across a broad range of risk strata.10,11 In the GRACE
registry, fatality rates for cardiogenic shock ranged
between 35% for patients receiving revascularization
and up to 74% in those not undergoing a pPCI procedure.4
Indeed, pPCI and coronary stenting are important pre-
dictors of in-hospital mortality.4 Thus, further research is a
particular clinical need in this patient population.
So far, it remained unclear whether DES implantation
during primary PCI would have a substantial impact on
outcomes in patients with cardiogenic shock. Indeed,
Champion et al.12 even reported a trend toward a higher
mortality after DES implantation. Therefore, they Copyright © 2015 Wolters Kluwer
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score ascertainment.strongly suggested that DES should not be the treatment
of choice in this patient population.12 These findings
were surprising, as a substantial reduction in restenosis
rate and revascularization has been documented using
DES in many trials enrolling patients with stable CAD13
and in two trials in patients with ACS.7,9 However, so far,
randomized trials in patients with ACS (i.e. HORIZONS-
AMI, clinical Evaluation of the Xience-V Stent in Acute
Myocardial INfArcTION and COMFORTABLE)
enrolled only a low proportion of patients with cardio-
genic shock and, thus, they did not address the question,
whether DESs indeed are advantageous in ACS patients
with hemodynamic compromise or high-risk coronary Health, Inc. All rights reserved.
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A 30-day (a) and long-term major adverse cardiac and cerebrovascular events (MACCEs) (b) for patients with drug-eluting stents (DESs, green) and
bare metal stents (BMSs, blue), after propensity score ascertainment.anatomy.7,9 Indeed, ACS studies enrolling all-comers
documented a markedly higher event rate compared with
these randomized trials.14
In contrast to previous reports,15,16 our results based on a
markedly larger study population strongly suggest that
the use of DESs in patients with cardiogenic shock does
indeed provide a substantial survival benefit and a
marked reduction in MACCE as compared with BMSs
both at 30 days and at long-term follow-up. The majority
of patients of this registry would not have been eligible
for randomized clinical trials because of their hemody-
namic instability, lesion complexity or because of the fact
that they had been intubated and/or resuscitated. The
clinical and anatomical complexity of the patients is
further reflected by their high SYNTAX and GRACE
score.17–19
As an early benefit of DES implantation appeared unli-
kely and baseline risk factors could affect the risk of
death, we performed a sensitivity analysis, whereby
mortality rates were examined 2 days after stent implan-
tation. Importantly, the reduction in long-term MACCE
and all-cause mortality with DESs remained significant,
indicating the potential for a true benefit of DES in
cardiogenic shock. As an operator bias in the selection
of BMS in patients with cardiogenic shock and a per-
ceived poor prognosis may have influenced the results,
we performed a propensity score analysis to adjust for
imbalances. After adjusting for measured confounders,
we confirmed a significantly lower rate of 30-day and
long-term all-cause mortality and a trend toward a lower
rate of MACCE.
The better outcome after DES implantation as compared
with BMS in cardiogenic shock at 30 days and during Copyright © 2015 Wolters Kluwelong-term follow-up may be related to the local release of
antiproliferative as well as anti-inflammatory agents
such as paclitaxel, sirolimus, everolimus, biolimus or
zotarolimus, which are known to inhibit inflammation
and neointimal proliferation. Indeed, potentially, such
anti-inflammatory and immunomodulatory compounds
released from DESs may even reduce the production
of cytokines such as interleukin-6 and serum amyloid A
found at the site of coronary occlusion and in turn affect
outcome in these high-risk patients. However, WBC
count and hsCRP did not differ in patients receiving a
DES or a BMS. Thus, a systemic anti-inflammatory effect
of DES is unlikely. However, a local inhibition of the
marked inflammatory response at the site of coronary
occlusion20,21 may still be involved, especially early after
DES placement when up to 80% of the drug is eluted
over 30 days.22
Although a reduction in in-stent restenosis has been well
documented already with first-generation DESs, a high
rate of late stent thrombosis initially gave rise to a lot of
concern as to their use in ACS wherein thrombus for-
mation is more common than in stable patients.23,24
Indeed, a recently published meta-analysis supported
the notion of an incremental increase of stent thrombosis
over time in patients receiving DESs.25 However, the
majority of randomized clinical trials do not address
outcomes beyond 1 year.9 In line with these observations,
the rate of definite stent thrombosis in our study overall
tended to be higher in patients receiving a DES com-
pared with those receiving a BMS. However, the differ-
ences were not significant. Conceptually, the slightly
higher rate of definite stent thrombosis after DES
implantation at the 30-day follow-up could be because
of technical issues, such as stent malapposition, residualr Health, Inc. All rights reserved.
228 Journal of Cardiovascular Medicine 2015, Vol 16 No 3dissections, thrombus compression and/or displacement,
thrombus burden and/or longer average stent length in
the DES group (Table 2).24 However, the anticipated
increased late stent thrombosis or very late stent throm-
bosis rate after DES implantation was not observed in our
study, although the mean follow-up of 30-day survivors
surpassed 2 years in the DES group. This observation is
in line with the data of recently published trials, in which
second-generation DESs reduced the rate of very late
stent thrombosis when compared with first-generation
DESs.26 Of note, based on these results, second-gener-
ation DESs were preferentially used by our operations
also in ACS patients with cardiogenic shock enrolled into
the present registry.
Study limitations
The present study is based on an observational single-
center registry. Thus, owing to its observational nature,
selection bias, in spite of our attempts to account for them
using propensity analysis, cannot be fully excluded.
Indeed, patients with diabetes mellitus, hyperlipidemia,
hypertension, NSTEMI and multivessel disease may be
more likely to be treated with DESs, than those with
complex lesions, unstable clinical conditions and per-
ceived bad outcome. However, the risk profiles of the
patients receiving DESs and BMSs were similar in this
registry. Therefore, we could not identify any bias regard-
ing the selected treatment strategy. In addition, potential
bias was further accounted for using propensity score
analysis.
Second, it is unclear whether the experience at our
hospital would be consistent with that of other institu-
tions where cardiogenic shock may be managed differ-
ently. Although we attempted to perform a propensity
score adjustment, this approach does not account for
unobservable differences (i.e. platelet activity, aspirin
resistance among others).27,28 Moreover, owing to the
observational character of the present study, we are not
able to provide the accurate time duration of the cardio-
genic shock before the PCI, which could additionally
influence our results. Furthermore, the majority of DESs
were implanted between 2010 and 2012 as compared with
2007 and 2009 (68 vs. 45%, P< 0.001). Therefore, the
influence of intensive care medicine improvement on the
better prognosis after DES implantation cannot be
excluded. However, the mean follow-up was similar in
both groups. Nevertheless, these additional treatment
options remain important considerations in patients with
cardiogenic shock. Therefore, future work, in particular
prospective randomized trials, is needed in this important
area.
Conclusion
Our observation is the first to indicate a survival benefit of
DES use in patients with cardiogenic shock. However,
owing to the importance of this observation for physicians Copyright © 2015 Wolters Kluwertaking care of patients with cardiogenic shock, this hypo-
thesis should be further tested in a prospective, rando-
mized clinical trial.
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